98%
921
2 minutes
20
Background: With the current trend in healthcare moving towards a more value-based approach, it is essential to understand what value encompasses.
Objectives: To develop an actionable value-based outcome set (VOS) for daily practice.
Methods: A mixed method approach was used consisting of four phases. Formerly, a systematic review was conducted, providing an overview of all patient-relevant outcomes defined in current literature. These 23 outcomes were then presented to a group of patients, using a modified nominal group technique (NGT), to establish whether these results represented all of their relevant outcomes. Subsequently, these outcomes were ranked according to importance by patients attending our academic specialized psoriasis clinic. A review of the literature was performed to assess which instruments were available and suitable to evaluate the outcomes in this VOS. Finally, a pilot feasibility test was performed amongst patients.
Results: Of the 23 outcomes, two were omitted from the ranking exercise after the NGT. In the ranking exercise, 120 patients participated. The median age was 50.0 (IQR 25.0) years and 36.7% were female. Median PASI score was 2.4 (IQR 5.2), and treatments varied from topicals to biologicals. The outcomes scored as most important were symptom control, treatment efficacy, confidence in care and control of disease. The least important outcomes were comorbidity control, productivity and cost of care. A significant difference was shown between the ranking of the outcomes (p < 0.001). In total, 12 instruments were selected, which are reported by both patient and provider, to measure the outcomes in this VOS. Median completion time for the patient part was 30 min (IQR 2.8).
Conclusions: This VOS is a first proposal to evaluate psoriasis care in a value-based manner. Measuring these outcomes can enable us to critically appraise and improve current care processes, within the reality of available resources, thereby increasing value for patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jdv.18696 | DOI Listing |
Vet Ophthalmol
September 2025
Ophthalmology Section, Equine Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Objective: To describe the use of transcorneal iris photocoagulation (TCIP) to improve intraocular visualization of intended incision lines, reduce hemorrhage, and facilitate excision of pigmented iridal tumors in four canine eyes and one feline eye.
Materials And Methods: A Rhodesian Ridgeback (treated bilaterally), a German Shepherd, a Labrador Retriever, and a Scottish Fold underwent sector iridectomy due to rapidly growing, pigmented, raised, iridal tumors affecting 1/4-1/3 of the iris circumference (3- to 4-clock hours). A diode laser was used to delineate the intended sector iridectomy incision lines, approximately 1-2 mm away from the grossly visible tumor margins, with the aim of improving visualization to achieve tumor-free margins and reduce tissue handling/trauma.
Vet Surg
September 2025
Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA.
Objective: To describe the long-term outcome of a horse that underwent a standing, ultrasound-guided, minimally invasive, biceps brachii tenotomy.
Study Design: Case report.
Animal: A 17-year-old Tennessee Walking Horse gelding.
Arthritis Rheumatol
September 2025
Washington DC Veterans Affairs Medical Center; Georgetown University, Washington, DC, USA.
Objective: To evaluate the clinical characteristics, social deprivation, insurance coverage, and medication use across regional subsets of patients with psoriatic arthritis (PsA) in the US.
Methods: A cross-sectional study of PsA patients in the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2020 and March2023 was conducted. Distribution of high disease activity (HDA - RAPID3>12), high comorbidity (RxRisk ≥90 percentile), high Area Deprivation Index (ADI ≥80), insurance coverage, prednisone ≥10mg daily, and all DMARD therapies across geographic regions were evaluated.
Haematologica
September 2025
Division of Hematology, Department of Medicine, The University of Colorado School of Medicine, Aurora CO 80045; Division of Hematology and Oncology, Department of Medicine, Rocky Mountain Regional VA, Aurora CO 80045.
Not available.
View Article and Find Full Text PDF